Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Operating Expenses (2016 - 2026)

Anika Therapeutics has reported Operating Expenses over the past 17 years, most recently at $24.5 million for Q1 2026.

  • Quarterly Operating Expenses rose 29.11% to $24.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $80.4 million through Mar 2026, up 2.28% year-over-year, with the annual reading at $74.9 million for FY2025, 7.7% down from the prior year.
  • Operating Expenses was $24.5 million for Q1 2026 at Anika Therapeutics, up from $18.5 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $35.4 million in Q1 2023 and troughed at -$18.9 million in Q4 2023.
  • The 5-year median for Operating Expenses is $21.5 million (2024), against an average of $19.5 million.
  • Year-over-year, Operating Expenses crashed 146.33% in 2022 and then skyrocketed 194.2% in 2024.
  • A 5-year view of Operating Expenses shows it stood at -$12.6 million in 2022, then plummeted by 49.9% to -$18.9 million in 2023, then surged by 194.2% to $17.8 million in 2024, then increased by 3.94% to $18.5 million in 2025, then skyrocketed by 32.12% to $24.5 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Operating Expenses are $24.5 million (Q1 2026), $18.5 million (Q4 2025), and $18.8 million (Q3 2025).